Cas No. 1455358-06-1, 1-(tert-butyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one

As an oral calcitonin gene-related peptide (CGRP) receptor antagonist, Ubrogepant offers fast-acting, effective relief for acute migraines without the typical adverse effects of triptans. This novel approach paves the way for a new era in migraine management, providing patients with a much-needed alternative. By incorporating Ubrogepant into your pharmaceutical portfolio, you can make a significant impact on improving the lives of migraine sufferers and advance neurological care.